HomeREGULATORY
REGULATORY

Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval
(Dec.5.2017)

Novo Nordisk’s once-weekly GLP-1 agent semaglutide hit a bump in Japan as a key health ministry advisory organ on December 4 put a hold on issuing a recommendation for the drug’s approval and decided to continue its deliberations ...
(LOG IN FOR FULL STORY)